Ultimately, our efforts are oriented toward proposing IL-20 subfamily cytokines as therapeutic target for neuroinflammatory pathologies, like MS, autism, Alzheimer’s disease, and post-stroke recovery. Here, IL20 is linked to early-onset autosomal dominant Alzheimer disease.